Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.

@article{Reinartz2010SuppressiveAR,
  title={Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.},
  author={Silke Reinartz and Jacobus Pfisterer and Andreas Du Bois and Christian Jackisch and Klaus H. Baumann and Uwe Wagner},
  journal={Human immunology},
  year={2010},
  volume={71 1},
  pages={
          36-44
        }
}
The results of several clinical trials have clearly demonstrated the potential of the anti-idiotype (anti-Id) vaccine abagovomab to induce cancer antigen 125 (CA-125)-specific immunity in ovarian cancer patients. Because of the central role of regulatory T cells (Tregs) in tumor immunology, we analyzed the frequency and suppressive activity of CD25(+)FoxP3(+) Tregs in 16 patients treated with abagovomab. During vaccination, mean frequencies of peripheral Treg with a CD4(+)CD25(+)FoxP3(+) CD127… CONTINUE READING